Davidson Investment Advisors cut its holdings in shares of Becton Dickinson (NYSE:BDX) by 2.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,379 shares of the medical instruments supplier’s stock after selling 1,341 shares during the quarter. Davidson Investment Advisors’ holdings in Becton Dickinson were worth $9,617,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Legacy Advisors LLC lifted its holdings in Becton Dickinson by 7,000.0% during the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 490 shares in the last quarter. Amica Retiree Medical Trust lifted its holdings in Becton Dickinson by 325.0% during the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 390 shares in the last quarter. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson during the 4th quarter worth approximately $109,000. FTB Advisors Inc. lifted its holdings in Becton Dickinson by 114.2% during the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 290 shares in the last quarter. Finally, Advisors Preferred LLC acquired a new stake in Becton Dickinson during the 4th quarter worth approximately $126,000. Institutional investors own 84.02% of the company’s stock.
In other Becton Dickinson news, EVP Thomas E. Polen, Jr. sold 1,877 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $227.00, for a total transaction of $426,079.00. Following the transaction, the executive vice president now directly owns 15,387 shares of the company’s stock, valued at approximately $3,492,849. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nabil Shabshab sold 10,209 shares of the firm’s stock in a transaction on Friday, May 11th. The stock was sold at an average price of $226.10, for a total transaction of $2,308,254.90. Following the transaction, the executive vice president now directly owns 12,476 shares in the company, valued at $2,820,823.60. The disclosure for this sale can be found here. Insiders sold a total of 21,656 shares of company stock worth $4,892,092 over the last ninety days. Insiders own 1.00% of the company’s stock.
Becton Dickinson (NYSE:BDX) last posted its earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 EPS for the quarter, beating the Zacks’ consensus estimate of $2.63 by $0.02. The firm had revenue of $4.22 billion for the quarter, compared to the consensus estimate of $4.12 billion. Becton Dickinson had a negative net margin of 0.46% and a positive return on equity of 14.27%. The company’s revenue was up 42.2% on a year-over-year basis. During the same period last year, the firm posted $2.30 EPS. research analysts forecast that Becton Dickinson will post 10.99 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 29th. Investors of record on Friday, June 8th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date is Thursday, June 7th. Becton Dickinson’s dividend payout ratio (DPR) is 31.65%.
A number of research firms have issued reports on BDX. ValuEngine upgraded shares of Becton Dickinson from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Citigroup upgraded shares of Becton Dickinson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $237.00 to $251.00 in a report on Tuesday, April 10th. Zacks Investment Research lowered shares of Becton Dickinson from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. BMO Capital Markets initiated coverage on shares of Becton Dickinson in a research report on Monday, March 5th. They issued a “market perform” rating and a $249.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on shares of Becton Dickinson from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Becton Dickinson has a consensus rating of “Buy” and a consensus price target of $241.19.
About Becton Dickinson
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.